Authors
Latest:
Long-Term Cabozantinib/Nivolumab Data Show Improved Survival in RCCManojkumar Bupathi, MD, MS, discusses the updated efficacy results of the CheckMate 9ER trial of cabozantinib plus nivolumab for patients with previously untreated advanced clear cell renal cell carcinoma.
Latest:
Unmet Needs in R/R DLBCLDr Grzegorz S. Nowakowski muses on the unmet needs of patients with DLBCL and the emerging treatment options he looks forward to.
Latest:
Selecting Treatment for Late-Stage SCLCAfshin Dowlati, MD, discusses treatment decision-making for patients with late-stage small cell lung cancer.
Latest:
Transforming Neuroendocrine Tumor Treatment With Lutetium OxodotreotideAman Chauhan, MD, discusses the mechanism and benefits of lutetium oxodotreotide.
Latest:
Molecular Characteristics Determine Subtypes of Small Cell Lung CancerQian Wang, MD, MPH, discusses the progress of research into the molecular pathways responsible for developing small cell lung cancer.
Latest:
Examining Molecular Targets in SarcomaMark Agulnik, MD, discusses advances in determining the molecular drivers of the tumor in the sarcoma space.
Latest:
Examining Pelabresib for Patients With MyelofibrosisJoseph M. Scandura, MD, PhD, discusses research regarding pelabresib for patients with myeloproliferative neoplasms.
Latest:
Immunotherapy Offers Hopeful Outcomes in Nonmelanoma Skin CancersNew and emerging treatment modalities for advanced nonmelanoma skin cancer provide hope for this patient subset.
Latest:
ctDNA Is Improving Oncology Care and Should Be Part of the Standard of CareMany oncologists, including surgeons, medical oncologists, and radiation oncologists, have already started to incorporate ctDNA testing as part of their standard practice to monitor treatment response and aid in the interpretation of equivocal imaging findings and in surveillance for recurrence.
Latest:
TAR-210's Potential to Improve Outcomes in Intermediate-Risk NMIBCRoger Li, MD, discusses what the future may hold for the use of TAR-210 for the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer with susceptible FGFR alterations.
Latest:
Sequencing Therapy With Novel Agents in Metastatic CholangiocarcinomaClinical pearls regarding molecular testing and treatment selection in metastatic cholangiocarcinoma.
Latest:
Phase 3 Study Demonstrates Intracranial Response in ALK+ NSCLCBenjamin Solomon, MBBS, PhD, discusses the intracranial responses observed in the CROWN trial of lorlatinib versus crizotinib in patients with ALK-positive non–small cell lung cancer.
Latest:
McIver Explores Treatment of a Patient With RET-Mutated Medullary Thyroid CancerDuring a virtual Targeted Oncology Case-Based Roundtable event, Bryan McIver, MD, PhD, discussed the case of a 58-year-old patient with RET-mutant medullary thyroid cancer.
Latest:
Using MRD to Predict Outcomes in Acute Myeloid LeukemiaSangeetha Venugopal, MD, MS, discusses how measurable residual disease is used during the course of treatment of AML.
Latest:
Pluvicto Approval Launches Theranostics in Prostate CancerAshok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.
Latest:
Combination of Venetoclax and Hypomethylating Agents Show Efficacy in AMLDanielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.
Latest:
RAD-SG Trial Evaluates RADiation Therapy and Sacituzumab Govitecan in MIBCOmar Mian, MD, PhD, provides an overview of the RAD-SG trial of RADiation therapy given with sacituzumab govitecan for bladder preservation in patients with muscle-invasive bladder cancer, which is currently in progress.
Latest:
Building a Patient-Centered Ecosystem Leads to Better CareWithin the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.
Latest:
Bhatt Recaps Trial of Ruxolitinib in Steroid Refractory Sclerotic cGVHDVijaya Raj Bhatt, MBBS, MS, discusses background and findings from a multicenter, phase 2 study of ruxolitinib for the treatment of patients with steroid refractory sclerotic chronic graft-versus-host disease.
Latest:
Investigating KRAS/TP53 Co-Alterations in Pancreatic CancerJashodeep Datta, MD, explains KRAS and TP53 co-alterations in patients with pancreatic cancer.
Latest:
Optimizing the Management of Melanoma: Future Directions in CareClosing out his discussion on the management of metastatic melanoma, expert oncologist Sajeve Thomas, MD, summarizes unmet needs and looks toward future evolutions in the treatment paradigm.
Latest:
Challenging Barriers to Community Oncology CareDipti Patel-Donnelly, MD, highlights challenges for physicians and patients when managing treatment of hematologic malignancies in the community setting.
Latest:
The Future of Neoadjuvant Immunotherapy in MIBCDr Terence Friedlander closes his discussion by highlighting ongoing clinicals in neoadjuvant MIBC treatment that excite him and speculates on how he would use immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant setting.
Latest:
Experts Compare Available Regimens for a Patient With Sarcomatoid FeaturesDuring a Targeted Oncology Case-Based Peer Perspective virtual event, Amir Mortazavi, MD andMoshe Ornstein, MD, MA discussed available treatment regimen for a patient with clear cell renal cell carcinoma and sarcomatoid features.
Latest:
HR+/HER2- Metastatic Breast Cancer: Future Directions in CareClosing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
Latest:
Adapting to Second-Line Restrictions of Niraparib in Ovarian CancerThe approved PARP inhibitor niraparib has been beneficial for patients with recurrent ovarian cancer, but new second-line restrictions for certain patients have led physicians to be more cautious when re-challenging these patients.
Latest:
Revolutionizing Lung Cancer Detection With Self-Taught AIAristotelis Tsirigos, PhD, discusses a self-taught artificial intelligence tool being developed to accurately diagnose cases of adenocarcinoma.
